You're contacting media contact of this press release

Title: Andarix Pharmaceuticals to Participate in the 17th Annual Outsourcing in Clinical Trials OCT East Coast Conference

Boston, MA, United States, 11th May 2026 - Andarix Pharmaceuticals, Inc., a clinical-stage radiopharmaceutical company developing targeted therapies for solid tumors and rare cancers, today announced its participation in the 17th Annual Outsourcing in Clinical Trials (OCT) East Coast Conference, to be held May 12–13, 2026, at the Hyatt Regency New Brunswick in New Brunswick, New Jersey.OCT East Coast is the premier gathering of clinical operations leaders, biopharmaceutical sponsors, contract research organizations (CROs), and technology and service providers focused on advancing the efficiency and quality of clinical trial execution. The conference provides a focused forum for operational best practices, partnering discussions, and emerging innovations in oncology and broader therapeutic development.Andarix will use its presence at OCT East Coast to engage prospective CRO partners and clinical development collaborators as the company advances Tozaride (¹⁸⁸Re-AX-188), its lead asset, toward expanded clinical evaluation. Tozaride is a rhenium-188-labeled somatostatin receptor subtype 2 (SSTR2)-targeted radiopharmaceutical supported by Phase I/II clinical data across 75 patients and four studies, with Orphan Drug Designations granted for lung and pancreatic cancer.“Our participation at OCT East Coast reflects Andarix’s commitment to building the operational infrastructure needed to bring Tozaride to patients efficiently and at scale. We look forward to engaging with experienced CRO partners and development experts who share our urgency in addressing cancers with limited therapeutic options,”said Chris Adams, Founder & Chief Executive Officer of Andarix Pharmaceuticals.About Tozaride (¹⁸⁸Re-AX-188)Tozaride is an SSTR2-targeted radiopharmaceutical incorporating rhenium-...

This press release is issued by King Newswire